In patients receiving adjuvant cemiplimab for high-risk cutaneous SCC, what is your standard surveillance strategy for detecting relapse?

Ultrasound (US), Computed Tomography (CT), Positron Emission Tomography (PET), and Magnetic Resonance Imaging (MRI) are all options for radiographic surveillance of patients at very high risk for cSCC disease relapse. Understanding the clinical presentation, tumor histology, and patient factors can ...

Clinically, I follow patients every 3–4 months for the first 2 years, then every 6 months through year 5, and annually thereafter. These visits include a full skin exam, careful assessment of the primary site and draining nodal basins, and review for any late or persistent immune-related toxicities....

Surveillance for those on adjuvant cemiplimab involves regular history and physical examinations, along with periodic radiologic examinations. Physical examinations are every 3-6 months, though in this very high-risk cohort, every 3 months is preferred. These exams should include skin examinations, ...